New drug combo shows promise for advanced prostate cancer across races

NCT ID NCT03098836

Completed Disease control Sponsor: Daniel George, MD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a combination of two drugs, apalutamide and abiraterone, plus prednisone, in 93 men with advanced prostate cancer that had spread and was no longer responding to hormone therapy. The goal was to see how long the cancer stayed under control and whether the drugs worked similarly in African American and Caucasian men. The men took the drugs daily in 4-week cycles, and the study tracked their cancer progression and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apalutamide and abiraterone acetate (with prednisone)
What this could lead to: If successful, this could show that a two-drug combination works well for advanced prostate cancer in both Black and White men, potentially leading to more personalized treatment.
What could go wrong: This is a small, early-phase study (Phase 2) with only 93 men, so results may not apply to everyone. The drugs can cause side effects like high blood pressure and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma Neoplasm Metastasis prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Chesapeake Urology Associates

Baltimore, Maryland, 21204, United States
Duke Cancer Center Cary

Cary, North Carolina, 27518, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Johnston Hematology and Oncology of Clayton

Clayton, North Carolina, 27520, United States
Johnston Memorial Hospital

Smithfield, North Carolina, 27577, United States
Maria Parham Hospital

Henderson, North Carolina, 27536, United States
Scotland Memorial Hospital

Laurinburg, North Carolina, 28352, United States
Southeastern Regional

Lumberton, North Carolina, 28358, United States
Spartanburg Regional

Spartanburg, South Carolina, 29303, United States
Tulane University

New Orleans, Louisiana, 70112, United States
UNC Lineberger Cancer Center

Chapel Hill, North Carolina, 27514, United States
Virginia Oncology Associates

Hampton, Virginia, 29303, United States
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.